WenTongGanPi decoction alleviates diarrhea-predominant irritable bowel syndrome by improving intestinal barrier

被引:2
|
作者
Li, Yaoguang [1 ]
Chen, Yangyang [2 ]
Liao, Zhengyue [3 ]
Liu, Yixin [3 ]
Liu, Chenhao [4 ]
Yang, Wenjing [3 ]
Bai, Jing [3 ]
Huang, Xinggui [4 ]
Hao, Yule [4 ]
Liu, Sijing [1 ,3 ]
Liu, Yi [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Coll Clin Med, Chengdu 611103, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 611103, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Coll Med Technol, Chengdu 611103, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Coll Basic Med Sci, Chengdu 610075, Peoples R China
关键词
WenTongGanPi decoction; Irritable bowel syndrome; Diarrhea; MAPK signal pathway; Intestinal barrier; Gut microbiota; CHAIN FATTY-ACIDS; Q-TOF-MS/MS; METABOLITE; MICROBIOTA; MAPK;
D O I
10.1016/j.jep.2024.118544
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: WenTongGanPi Decoction (WTGPD) is a representative medical practice of the Fuyang School of Traditional Chinese Medicine (TCM), which originated from the classical Lu's Guizhi method. WTGPD places emphasis on the balance and functionality of yang qi, and is effective in treating TCM symptoms related to liver qi stagnation and spleen yang deficiency. In TCM, diarrhea-predominant irritable bowel syndrome (IBS-D) is often diagnosed as liver depression and spleen deficiency, and the use of WTGPD has shown significant therapeutic effect. However, the underlying mechanism of WTGPD treating IBS-D remains unclear. Aim of the study: To explore the effect and mechanism of WTGPD in the treatment of IBS-D. Materials and methods: An IBS-D model with liver depression and spleen deficiency was constructed by chronic immobilization stress stimulation and sennae folium aqueous gavage. The impact of WTGPD on IBS-D rats was evaluated through measurements of body weight, fecal water content, and abdominal withdrawal reflex (AWR). Intestinal permeability was assessed using hematoxylin-eosin (HE), alcian blue-periodic acid schiff (AB-PAS), immunofluorescence (IF) staining, and quantitative real-time PCR (qRT-PCR). The components of WTGPD were analyzed using UPLC-Q-TOF-MS. The underlying mechanisms were investigated through network pharmacology, transcriptomics sequencing, western blot (WB), molecular docking, and 16S rRNA sequencing. Results: WTGPD treatment effectively alleviated diarrhea and abnormal pain in IBS-D rats (P P < 0.05). It enhanced the intestinal barrier function by improving colonic structure and increasing the expression of tight junction proteins (P P < 0.05). A total of 155 components were identified in WTGPD. Both network pharmacology and transcriptomics sequencing analysis highlighted MAPK as the key signaling pathway in WTGPD's anti-IBS-D effect. The WB results showed a significant decrease in p-p38, p-ERK and p-JNK expression after WTGPD treatment (P P < 0.0001). Guanosine, adenosine and hesperetin in WTGPD may be involved in regulating the phosphorylation of p38, ERK and JNK. Additionally, WTGPD significantly enhanced microbial diversity and increased the production of colonic valeric acid in IBS-D rats (P P < 0.01). Conclusion: In conclusion, our findings suggest that WTGPD can effectively alleviate IBS-D and improve intestinal barrier likely via inhibiting MAPK signal pathway and improving micobial dysbiosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Review: The Role of MOP and DOP Receptors in Treatment of Diarrhea-predominant Irritable Bowel Syndrome
    Jarmuz, Agata
    Zielinska, Marta
    Len, Karolina
    Banaszek, Martyna
    Storr, Martin
    Fichna, Jakub
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (18) : 1462 - 1469
  • [32] Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
    Arrouk, Rami
    Herdes, Rachel E.
    Karpinski, Aryn C.
    Hyman, Paul E.
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2018, 9 : 129 - 133
  • [33] EFFECTS OF A PROPRIETARY BACILLUS COAGULANS PREPARATION ON SYMPTOMS OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME
    Dolin, B. J.
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2009, 31 (10): : 655 - 659
  • [34] Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs
    Mozaffari, Shilan
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (03) : 219 - 228
  • [35] A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
    Chen, Chunqiu
    Tao, Chunhua
    Liu, Zhongchen
    Lu, Meiling
    Pan, Qiuhui
    Zheng, Lijun
    Li, Qing
    Song, Zhenshun
    Fichna, Jakub
    PHYTOTHERAPY RESEARCH, 2015, 29 (11) : 1822 - 1827
  • [36] Structure and Metabolic Activity of the Gut Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Combined with Functional Dyspepsia
    Kovaleva, Aleksandra
    Poluektova, Elena
    Maslennikov, Roman
    Zolnikova, Oxana
    Shifrin, Oleg
    Kudryavtseva, Anna
    Krasnov, George
    Fedorova, Maria
    Karchevskaya, Anna
    Ivashkin, Vladimir
    GASTROINTESTINAL DISORDERS, 2023, 5 (03): : 296 - 309
  • [37] The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
    Tian, Zhenyi
    Zhuang, Xiaojun
    Luo, Mei
    Yin, Wei
    Xiong, Lishou
    BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [38] The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome
    Hod, Keren
    Dekel, Roy
    Cohen, Nathaniel Aviv
    Sperber, Ami
    Ron, Yishai
    Boaz, Mona
    Berliner, Shlomo
    Maharshak, Nitsan
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30 (12)
  • [39] Baizhu shaoyao decoction restores the intestinal barrier and brain-gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a
    Wei, Yuanyuan
    Fan, Yimeng
    Huang, Sijuan
    Lv, Jianyu
    Zhang, Yannan
    Hao, Zhihui
    PHYTOMEDICINE, 2024, 122
  • [40] Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways
    Xie, Ying
    Zhan, Xin
    Tu, Jiyuan
    Xu, Kang
    Sun, Xiongjie
    Liu, Chunlian
    Ke, Chang
    Cao, Guosheng
    Zhou, Zhongshi
    Liu, Yanju
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 272